Dr. Bartosz Chmielowski, MD
Claim this profileUCLA
Area of expertise
Melanoma
Bartosz Chmielowski, MD has run 13 trials for Melanoma. Some of their research focus areas include:
Skin Cancer
Bartosz Chmielowski, MD has run 7 trials for Skin Cancer. Some of their research focus areas include:
Affiliated Hospitals
UCLA
University Of California, Los Angeles
Clinical Trials Bartosz Chmielowski, MD is currently running
IDE196 Combinations
for Solid Tumors
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity. As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.
Recruiting
1 award
Phase 1 & 2
9 criteria
Anlotinib
for Alveolar Soft Part Sarcoma
THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one-third of the participants will receive IV dacarbazine.
Recruiting
1 award
Phase 3
More about Bartosz Chmielowski, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Bartosz Chmielowski, MD has experience with
- Nivolumab
- Pembrolizumab
- Ipilimumab
- Dacarbazine
- IDE196
- Binimetinib
Breakdown of trials Bartosz Chmielowski, MD has run
Skin Cancer
Eye Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bartosz Chmielowski, MD specialize in?
Bartosz Chmielowski, MD focuses on Melanoma and Skin Cancer. In particular, much of their work with Melanoma has involved Stage IV patients, or patients who are BRAF positive.
Is Bartosz Chmielowski, MD currently recruiting for clinical trials?
Yes, Bartosz Chmielowski, MD is currently recruiting for 5 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Bartosz Chmielowski, MD has studied deeply?
Yes, Bartosz Chmielowski, MD has studied treatments such as Nivolumab, Pembrolizumab, Ipilimumab.
What is the best way to schedule an appointment with Bartosz Chmielowski, MD?
Apply for one of the trials that Bartosz Chmielowski, MD is conducting.
What is the office address of Bartosz Chmielowski, MD?
The office of Bartosz Chmielowski, MD is located at: UCLA, Los Angeles, California 90095 United States. This is the address for their practice at the UCLA.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.